The role of autologous hemаtopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma with adverse factors of prognosis
Samarina S.V., Nazarova E.L., Minaeva N.V., Zorina N.A., Khorobrykh M.N., Zotina E.N. Federal State Budget Institution of ScienceKirov Scientific Research Institute of Hematology and Blood Transfusion of Federal Medical Biological Agency, 72 Krasnoarmeyskaya str., Kirov, Russian Federation, 610027.
Gritsaev S.V. 2Federal State Budget Institution Russian Research Institution of Hematology and Transfusiology of Federal Medical Biological Agency, 2-ya Sovetskaya str., 16, Saint-Petersburg, Russian Federation, 191024.
To determine the role of autologous stem cell transplantation (autoHSCT) in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and rationale to the need of improving the postremission therapy retrospective analyses of 38 patients survival has been made. Three groups of patients were formed according to the effectiveness of induction and reinduction therapy and carrying out of autoHSCT. Median of follow-up period was 51 months. Оverall survival was worse in patients with early relapse and resistant form of DLBCL without autoHSCT compared with patients to whom transplantation was performed in first remission or in relapse: 10 months vs the median, which not achieved in the second and third groups (р<0,001). The conclusion is - the advisability of autoHSCT including in the treatment algorithm of patients with unfavorable types of DLBCL and the need to develop new treatment approaches in elderly or comorbidity patients who can not perform autoHSCT.
1. Crump M., Neelapu S.S., Farooq U. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study // Blood. -2017. -Vol.130, N 16. - R.1800-1808.
2. Statistika zlokachestvennih novoobrazovanii v Rossii i stranah SNG v 2012 g. / Davidov M.I., Aksel E.M. - M.: Izdatelskaya gryppa RONC, 2014. - 226?s.
3. Gavrilina O.A., Gabeeva N.G., Morozova A.K. idr. Rol visokodoznoi himioterapii transplantacii aytologichnih stvolovih kletok krovi y pacientov s diffyznoi V-krypnokletochnoi limfomoi // Terapevticheskii arhiv. - 2013. - T. 85, ?7. - S. 90-97.
4. Ziepert M., Hasenclever D., Kuhnt E. et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era // Journal of Clinical Oncology. - 2010. - Vol. 28, N 14. - R. 2373-2380.
5. Pfreundschuh M., Kuhnt E., Trumper L. et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group // Lancet Oncology. -2011. - Vol. 12, N 11- P. 1013-1022.
6. Recher C., Coiffier B., Haioun C. et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial // Lancet. - 2011. - Vol. 378, N 9806. - P. 1858-1867.
7. NCCN Guidelines for Treatment of Non-Hodgkin Lymphoma. http://http://www.nccn.org. Accessed, April 20, 2018.
8. Philip T., Guglielmi C., Hagenbeek A. et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin?s lymphoma // The New England Journal of Medicine. - 1995. - Vol. 333, N 23. - P. 1540-1545.
9. Gisselbrecht C., Glass B., Mounier N. et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era //Journal of Clinical Oncology. - 2010. - Vol. 28, N 27. - P. 4184-4190.
10. Tarella C., Zanni M., Magni M. et al. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter GruppoItalianoTerapie Innovative neiLinfomi survey // Journalof Clinical Oncology. - 2008. - Vol. 26, N 19. - P.3166-3175.
11. Rosenberg S.A. Validity of the Ann Arbor staging classification for the non-Hodgkin?s lymphomas // Cancer Treatment Report. - 1997. - Vol. 61, N 6. - P. 1023-1027.
12. Coifﬁer B., Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure - what to do? // Hematology. - 2016. - Vol. 2016, N 1. - R. 366-378.
13. Sieniawski M., Staak O., Glossmann J.P. et al. Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma // Annals of Hematology. - 2007. - Vol. 86, N 2. - P. 107-115.
14. Shimoni A., Avivi I., Rowe J. et al. A randomized study comparing yttrium-90 ibritumomabtiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma // Cancer. -2012. - Vol. 118, N19. - P. 4706-4714.
15. Kim J.E., Lee D.H., Yoo C. et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin?s lymphoma patients: a single center comparative analysis of efficacy and toxicity // Leukemia Research. - 2011. - Vol. 35. - P. 183-187.
16. FangX., Xiu B., YangZ. et al. The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma // Medicine (Baltimore). - 2017. - Vol. 96, N 15. - e6398.
17. Kiyasu J., Miyoshi H., Hirata A., et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma // Blood. - 2015. - Vol. 126, N 19. - P. 2193-2201.
18. Rosenwald A., Wright G., Leroy K.et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma // Journal of Experimental Medicine. - 2003. - Vol. 198. - R. 851-862.